|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DTX3L |
Gene summary for DTX3L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DTX3L | Gene ID | 151636 |
| Gene name | deltex E3 ubiquitin ligase 3L | |
| Gene Alias | BBAP | |
| Cytomap | 3q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | Q8TDB6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 151636 | DTX3L | HTA11_347_2000001011 | Human | Colorectum | AD | 3.69e-10 | 3.15e-01 | -0.1954 |
| 151636 | DTX3L | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.97e-10 | 3.84e-01 | -0.059 |
| 151636 | DTX3L | HTA11_99999970781_79442 | Human | Colorectum | MSS | 8.75e-10 | 3.67e-01 | 0.294 |
| 151636 | DTX3L | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.43e-04 | 7.68e-01 | 0.3487 |
| 151636 | DTX3L | HTA11_99999971662_82457 | Human | Colorectum | MSS | 7.51e-03 | 2.04e-01 | 0.3859 |
| 151636 | DTX3L | LZE2T | Human | Esophagus | ESCC | 2.66e-05 | 5.04e-01 | 0.082 |
| 151636 | DTX3L | LZE4T | Human | Esophagus | ESCC | 6.17e-12 | 4.16e-01 | 0.0811 |
| 151636 | DTX3L | LZE5T | Human | Esophagus | ESCC | 1.07e-03 | 1.94e-01 | 0.0514 |
| 151636 | DTX3L | LZE7T | Human | Esophagus | ESCC | 2.00e-02 | 1.91e-01 | 0.0667 |
| 151636 | DTX3L | LZE8T | Human | Esophagus | ESCC | 2.31e-11 | 2.99e-01 | 0.067 |
| 151636 | DTX3L | LZE20T | Human | Esophagus | ESCC | 5.58e-05 | 1.93e-01 | 0.0662 |
| 151636 | DTX3L | LZE22T | Human | Esophagus | ESCC | 1.42e-04 | 3.05e-01 | 0.068 |
| 151636 | DTX3L | LZE24T | Human | Esophagus | ESCC | 8.89e-32 | 7.58e-01 | 0.0596 |
| 151636 | DTX3L | LZE6T | Human | Esophagus | ESCC | 5.75e-03 | 1.78e-01 | 0.0845 |
| 151636 | DTX3L | P1T-E | Human | Esophagus | ESCC | 2.67e-14 | 6.26e-01 | 0.0875 |
| 151636 | DTX3L | P2T-E | Human | Esophagus | ESCC | 2.24e-24 | 5.20e-01 | 0.1177 |
| 151636 | DTX3L | P4T-E | Human | Esophagus | ESCC | 1.37e-12 | 2.09e-01 | 0.1323 |
| 151636 | DTX3L | P5T-E | Human | Esophagus | ESCC | 6.67e-17 | 3.54e-01 | 0.1327 |
| 151636 | DTX3L | P8T-E | Human | Esophagus | ESCC | 1.87e-44 | 8.31e-01 | 0.0889 |
| 151636 | DTX3L | P9T-E | Human | Esophagus | ESCC | 1.34e-33 | 7.42e-01 | 0.1131 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190332134 | Oral cavity | NEOLP | negative regulation of protein modification by small protein conjugation or removal | 33/2005 | 95/18723 | 3.57e-10 | 3.07e-08 | 33 |
| GO:000961531 | Oral cavity | NEOLP | response to virus | 80/2005 | 367/18723 | 3.70e-10 | 3.14e-08 | 80 |
| GO:005109833 | Oral cavity | NEOLP | regulation of binding | 77/2005 | 363/18723 | 2.91e-09 | 1.76e-07 | 77 |
| GO:005134833 | Oral cavity | NEOLP | negative regulation of transferase activity | 62/2005 | 268/18723 | 3.19e-09 | 1.91e-07 | 62 |
| GO:005109933 | Oral cavity | NEOLP | positive regulation of binding | 46/2005 | 173/18723 | 3.51e-09 | 2.04e-07 | 46 |
| GO:003209231 | Oral cavity | NEOLP | positive regulation of protein binding | 29/2005 | 85/18723 | 6.62e-09 | 3.54e-07 | 29 |
| GO:190382932 | Oral cavity | NEOLP | positive regulation of cellular protein localization | 61/2005 | 276/18723 | 2.63e-08 | 1.14e-06 | 61 |
| GO:001657031 | Oral cavity | NEOLP | histone modification | 88/2005 | 463/18723 | 5.59e-08 | 2.23e-06 | 88 |
| GO:190018031 | Oral cavity | NEOLP | regulation of protein localization to nucleus | 37/2005 | 136/18723 | 6.09e-08 | 2.39e-06 | 37 |
| GO:000020931 | Oral cavity | NEOLP | protein polyubiquitination | 53/2005 | 236/18723 | 1.22e-07 | 4.38e-06 | 53 |
| GO:005160731 | Oral cavity | NEOLP | defense response to virus | 57/2005 | 265/18723 | 1.97e-07 | 6.55e-06 | 57 |
| GO:014054631 | Oral cavity | NEOLP | defense response to symbiont | 57/2005 | 265/18723 | 1.97e-07 | 6.55e-06 | 57 |
| GO:004339332 | Oral cavity | NEOLP | regulation of protein binding | 45/2005 | 196/18723 | 5.56e-07 | 1.65e-05 | 45 |
| GO:000283131 | Oral cavity | NEOLP | regulation of response to biotic stimulus | 65/2005 | 327/18723 | 5.93e-07 | 1.74e-05 | 65 |
| GO:004311231 | Oral cavity | NEOLP | receptor metabolic process | 40/2005 | 166/18723 | 6.24e-07 | 1.82e-05 | 40 |
| GO:005144433 | Oral cavity | NEOLP | negative regulation of ubiquitin-protein transferase activity | 11/2005 | 19/18723 | 6.90e-07 | 1.93e-05 | 11 |
| GO:190018231 | Oral cavity | NEOLP | positive regulation of protein localization to nucleus | 26/2005 | 87/18723 | 7.70e-07 | 2.14e-05 | 26 |
| GO:001657431 | Oral cavity | NEOLP | histone ubiquitination | 16/2005 | 47/18723 | 1.65e-05 | 2.83e-04 | 16 |
| GO:005105231 | Oral cavity | NEOLP | regulation of DNA metabolic process | 63/2005 | 359/18723 | 5.48e-05 | 7.44e-04 | 63 |
| GO:200102031 | Oral cavity | NEOLP | regulation of response to DNA damage stimulus | 43/2005 | 219/18723 | 6.13e-05 | 8.19e-04 | 43 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa043306 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
| hsa0433013 | Esophagus | ESCC | Notch signaling pathway | 42/4205 | 62/8465 | 2.97e-03 | 7.97e-03 | 4.08e-03 | 42 |
| hsa043305 | Oral cavity | OSCC | Notch signaling pathway | 44/3704 | 62/8465 | 1.26e-05 | 5.55e-05 | 2.83e-05 | 44 |
| hsa0433012 | Oral cavity | OSCC | Notch signaling pathway | 44/3704 | 62/8465 | 1.26e-05 | 5.55e-05 | 2.83e-05 | 44 |
| hsa0433021 | Oral cavity | NEOLP | Notch signaling pathway | 21/1112 | 62/8465 | 2.23e-05 | 1.87e-04 | 1.18e-04 | 21 |
| hsa0433031 | Oral cavity | NEOLP | Notch signaling pathway | 21/1112 | 62/8465 | 2.23e-05 | 1.87e-04 | 1.18e-04 | 21 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DTX3L | SNV | Missense_Mutation | novel | c.552N>G | p.Ile184Met | p.I184M | Q8TDB6 | protein_coding | deleterious(0) | possibly_damaging(0.808) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DTX3L | SNV | Missense_Mutation | rs762198657 | c.779N>T | p.Arg260Ile | p.R260I | Q8TDB6 | protein_coding | deleterious(0.01) | possibly_damaging(0.548) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DTX3L | SNV | Missense_Mutation | novel | c.564G>C | p.Leu188Phe | p.L188F | Q8TDB6 | protein_coding | tolerated(0.09) | benign(0.065) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| DTX3L | SNV | Missense_Mutation | rs376434730 | c.1018N>A | p.Glu340Lys | p.E340K | Q8TDB6 | protein_coding | tolerated(0.64) | benign(0.006) | TCGA-AR-A255-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | SD |
| DTX3L | SNV | Missense_Mutation | c.325N>A | p.Ala109Thr | p.A109T | Q8TDB6 | protein_coding | tolerated(0.51) | benign(0.015) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| DTX3L | insertion | In_Frame_Ins | novel | c.2146_2147insGAATGT | p.Pro716delinsArgMetSer | p.P716delinsRMS | Q8TDB6 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DTX3L | insertion | Frame_Shift_Ins | novel | c.2147_2148insTTCATTGGCTGGAA | p.Glu717SerfsTer16 | p.E717Sfs*16 | Q8TDB6 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DTX3L | insertion | Frame_Shift_Ins | novel | c.597_598insATAAAAC | p.Gln200IlefsTer27 | p.Q200Ifs*27 | Q8TDB6 | protein_coding | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DTX3L | insertion | Nonsense_Mutation | novel | c.1347_1348insGGGCATACATAACCACACTGTGCCCTAGTATC | p.Arg450GlyfsTer4 | p.R450Gfs*4 | Q8TDB6 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
| DTX3L | SNV | Missense_Mutation | novel | c.544N>C | p.Glu182Gln | p.E182Q | Q8TDB6 | protein_coding | deleterious(0.01) | benign(0.352) | TCGA-C5-A1M7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |